GE HealthCare Technologies Inc.
(NASDAQ:GEHC) stock rose Wednesday after the company reported second-quarter results that topped Wall Street estimates, driven by strength in its imaging and pharmaceutical diagnostics businesses.
The medical technology company reported adjusted earnings of $1.13 per share, exceeding the analyst consensus estimate of $1.03.
Revenue increased 5.7% year over year to $5.30 billion, beating the consensus estimate of $5.26 billion.
GE HealthCare ended the second quarter with a record backlog of $23.9 billion, up $2.6 billion from a year earlier, as strong demand for its imaging equipment, pharmaceutical diagnostics portfolio and AI-enabled products drove 11.1% organic orders growth.
